In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...

Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...

Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...

The Medicines Agency of Sweden, MPA, has authorized Herantis Pharma Plc`s ("Herantis") first-in-human clinical study of the company`s investigational product CDNF for the treatment of Parkinson`s ...

Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population. It affects dopamine-producing nerve cells in the brain ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET ...

Figure: Solution structure of human MANF protein. PDB ID: 2KVD [7]. Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived neurotrophic factor (MANF) form an evolutionary ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...